MME and cancer: These findings are corroborated by our observation that NEP promoter methylation specifically associated with decreased survival in stage I IDC patients (Figure 6e), suggesting that NEP methylation could be useful in predicting early-stage cancers that are inherently more aggressive and could help inform therapeutic strategies in these patients.